Beijing-based Genetron Health has received an undisclosed amount, but is running into “several hundred millions” of renminbi in a Series B financing led by VCanbio Cell and Gene Engineering, a biotech company listed on the Shanghai Stock Exchange.
Established two years ago with a focus on genome testing and cancer screening, prevention and treatment, Genetron plans to use the new funding to expand marketing channels, enhance product lines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?